179 related articles for article (PubMed ID: 37903998)
1. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
Attia S; Guirguis M; Le LQ; Chhabra A
Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
[TBL] [Abstract][Full Text] [Related]
2. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.
Friedrich RE; Nörnberg LKN; Hagel C
Anticancer Res; 2022 May; 42(5):2327-2340. PubMed ID: 35489721
[TBL] [Abstract][Full Text] [Related]
4. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
5. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
6. VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop.
Bonsang B; Maksimovic L; Maille P; Martin N; Laurendeau I; Pasmant E; Bièche I; Deschamps J; Wolkenstein P; Ortonne N
Ann Diagn Pathol; 2022 Oct; 60():151997. PubMed ID: 35777330
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study.
Friedrich RE; Nörnberg LKN; Hagel C
Anticancer Res; 2022 Mar; 42(3):1247-1261. PubMed ID: 35220215
[TBL] [Abstract][Full Text] [Related]
8. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
10. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
12. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
13. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
[TBL] [Abstract][Full Text] [Related]
14. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
Mautner VF; Asuagbor FA; Dombi E; Fünsterer C; Kluwe L; Wenzel R; Widemann BC; Friedman JM
Neuro Oncol; 2008 Aug; 10(4):593-8. PubMed ID: 18559970
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ristow I; Madesta F; Well L; Shenas F; Wright F; Molwitz I; Farschtschi S; Bannas P; Adam G; Mautner VF; Werner R; Salamon J
Neuro Oncol; 2022 Oct; 24(10):1790-1798. PubMed ID: 35426432
[TBL] [Abstract][Full Text] [Related]
16. Nerve ultrasound in neurofibromatosis type 1: A follow-up study.
Telleman JA; Stellingwerff MD; Brekelmans GJ; Visser LH
Clin Neurophysiol; 2018 Feb; 129(2):354-359. PubMed ID: 29288991
[TBL] [Abstract][Full Text] [Related]
17. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
[TBL] [Abstract][Full Text] [Related]
18. Surgery for Peripheral Nerve Sheath Tumours of the Buttocks, Legs and Feet in 90 Patients With Neurofibromatosis Type 1.
Friedrich RE; Tuzcu CT
In Vivo; 2021; 35(2):889-905. PubMed ID: 33622881
[TBL] [Abstract][Full Text] [Related]
19. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions.
Zhou H; Coffin CM; Perkins SL; Tripp SR; Liew M; Viskochil DH
Am J Surg Pathol; 2003 Oct; 27(10):1337-45. PubMed ID: 14508395
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
